Marley Fenella, Lockett Melanie, Gompels Mark, Grammatikos Alexandros
Department of Gastroenterology and Hepatology, North Bristol NHS Trust, Bristol, UK.
Department of Immunology, North Bristol NHS Trust, Bristol, UK.
Immunol Res. 2024 Dec 18;73(1):19. doi: 10.1007/s12026-024-09559-5.
CVID (common variable immunodeficiency) is associated with a variety of gastrointestinal disorders including those mimicking Crohn's disease and ulcerative colitis. At present there is no clear trial data for the treatment of CVID enteropathy. There are no specific recommendations for treatment; however, it is commonly treated in a similar manner to inflammatory bowel disease, with corticosteroids, 5-aminosalicylates (5-ASA), azathioprine and anti-TNF therapy all being used. We describe the case of a 54-year-old with CVID-enteropathy presenting with diarrhoea and evidence of granulomatous inflammation on colonic biopsies. He was successfully treated with ustekinumab following failure/intolerance of prednisolone, 5-ASA and azathioprine. Features of CVID-enteropathy improved both clinically and histologically, with no evidence of serious treatment-related side effects.
普通变异型免疫缺陷（CVID）与多种胃肠道疾病相关，包括那些酷似克罗恩病和溃疡性结肠炎的疾病。目前尚无关于治疗CVID肠病的明确试验数据。对于治疗没有具体的推荐；然而，其治疗方式通常与炎症性肠病相似，使用皮质类固醇、5-氨基水杨酸（5-ASA）、硫唑嘌呤和抗TNF治疗。我们描述了一例54岁患有CVID肠病的患者，其表现为腹泻，结肠活检有肉芽肿性炎症证据。在泼尼松龙、5-ASA和硫唑嘌呤治疗失败/不耐受后，他使用优特克单抗成功治愈。CVID肠病的特征在临床和组织学上均有改善，且没有严重的治疗相关副作用的证据。
